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Abstract
Recent studies have shown that on one hand, tumors need to obtain a sufficient energy supply, and on the other
hand they must evade the body’s immune surveillance. Because of their metabolic reprogramming characteristics,
tumors can modify the physicochemical properties of the microenvironment, which in turn affects the biological
characteristics of the cells infiltrating them. Regulatory T cells (Tregs) are a subset of T cells that regulate immune
responses in the body. They exist in large quantities in the tumor microenvironment and exert immunosuppressive
effects. The main effect of tumor microenvironment on Tregs is to promote their differentiation, proliferation,
secretion of immunosuppressive factors, and chemotactic recruitment to play a role in immunosuppression in
tumor tissues. This review focuses on cell metabolism reprogramming and the most significant features of the
tumor microenvironment relative to the functional effects on Tregs, highlighting our understanding of the
mechanisms of tumor immune evasion and providing new directions for tumor immunotherapy.
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Background
A tumor is a type of polygenic disease in which malig-
nant cell proliferation is caused by a variety of onco-
genic factors that promote abnormal gene expression
and regulation in the body [1]. It differs from the
body’s normal tissue cells, and is mainly characterized
by the following ten characteristics: unlimited prolifer-
ation, resistance to apoptosis, evasion of growth inhibi-
tory factors, invasion and metastasis, stimulation of
angiogenesis, continuous production of proliferative
signals, resistance to cellular energy metabolism, gen-
omic instability, evasion of immune suppression, and
enhancement of tumor-related inflammatory responses
[2–4]. Acquisition of these characteristics is insepar-
able from changes in the cells themselves and the in-
fluence of the surrounding environment. The internal
environment in which tumor cells grow is called the
tumor microenvironment, which consists of the extra-
cellular matrix, myofibroblasts, cytokines, fibroblasts,
neuroendocrine cells, adipocytes, immune-related cells,
and vasculature [5–8].Tumor cells can affect the physico-
chemical properties, components, and cytokines of the
tumor microenvironment, making it more conducive to
their growth, metastasis, and invasion [9–13]. At the same
time, changes in tumor microenvironment play an import-
ant role in all stages of tumor development, inhibiting or
promoting tumor growth. The interaction between the
two affects the whole process of tumor growth, and mu-
tual adaptation maintains the dynamic balance of tumor
microenvironment [14–19].
Owing to changes in their physiological characteris-
tics, tumor cells promote a series of changes in the
tumor microenvironment [20–23]. Rapidly growing
tumor cells and mesenchymal cells lead to a decrease
in local oxygen content and thus to a microenviron-
ment in an oxygen-starved state, with the most severe
hypoxia in the center of the tumor and a gradient de-
crease from external to internal oxygen content.
Tumor growth to 1–2 mm in diameter stimulates local
angiogenesis [24], and local hypoxia induces the ex-
pression of vascular endothelial growth factor (VEGF),
which in turn promotes the formation of blood vessels
in tumors [24, 25]. However, owing to the abnormal
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tumor microenvironment, new blood vessels often
have uneven distribution, large capillary distance, short
arteriovenous circuit, incomplete endothelial cells, and
ruptured basal membranes [26]. Therefore, these local-
ized microvessels cannot improve the state of hypoxia.
With changes in the tumor microenvironment, the me-
tabolism of tumor cells is also quite different from that
of normal cells. The most significant difference is the
Warburg effect, in which, compared with normal cells,
tumor cells obtain energy through anaerobic glycolysis
even under oxygen-rich conditions [27, 28]. At the
same time, hypoxia causes high expression levels of
hypoxia-inducible factor (HIF) in cells. This in turn
promotes the expression of glycolysis-related proteins
[29], and changes in glucose metabolism lead to the
massive production of lactic acid metabolites. An
oncogene such as c-myc is activated by tumor cells and
up-regulates the expression of lactate dehydrogenase A
(LDH-A) and promotes the conversion of pyruvate to
lactic acid [30]. This leads to an increase in lactate
content and low pH in tumor cells. To avoid the
effects of intracellular lactic acid on basal metabolic
activity, the efficiency of the monocarboxylate trans-
porter (MCT) on the cell membrane is increased, re-
moving excess lactic acid from the cell [31]. This
causes the tumor microenvironment to be at a low pH.
HIF can induce high expression levels of carbonic
anhydrase (CA) in tumor cells, which catalyzes the re-
action of CO2 with H2O to generate carbonic acid [32].
Stimulation of various types of carcinogens and cyto-
kines leads to disturbances in the acid-base balance in
tumor cells. Tumor cells promote an efflux of intracel-
lular hydrogen ions by up-regulating hydrogen ion-re-
lated transport proteins in the cell membrane [33].
The above changes will further exacerbate the low pH
of the microenvironment. In addition, de novo synthe-
sis of fatty acids in tumor cells is also enhanced [34,
35]. Glutamine metabolism is enhanced, and the me-
tabolism of other amino acids and nucleic acids also
changes [36, 37]. These metabolic changes promote
tumor cell proliferation, metastasis, and invasion [38–
40] and also cause changes to the microenvironment
of the tumor, affecting other cells infiltrating the tumor
tissue. Metabolic changes occur not only in tumor cells,
but also in immune cells infiltrated in the tumor tissue
that undergo metabolic reprogramming to accommodate
functional changes.
During proliferation and metastasis, tumor cells need
to obtain enough energy and reaction substrates to sat-
isfy their own metabolism [41–44], and it is necessary
to escape the surveillance and elimination of abnormal
tissue cells by the immune system [45]. The immune
evasion of tumor cells occurs in two ways: covering the
self-antigens to hide or remove the target that can be
recognized by the host immune system, also known as
antigen coverage; or secretion of immunosuppressive
cytokines to inhibit the immune effector cells or induc-
tion of suppressive immune cells to exert immunosup-
pressive effects [46]. Tregs belong to a T cell subgroup
with regulatory immune functions. These cells partici-
pate in the immune escape of tumor cells mainly
through the induction of immune incompetence and
immunosuppression [47]. Clinical studies have found a
large infiltration of Tregs in tumor tissues of patients,
and their amount is closely related to the prognosis of
patients [48, 49]. Some tumors can be treated by re-
versing local Tregs levels in tumor tissue [50, 51].
Animal experiments showed that tumor growth is
positively correlated with Tregs local content in tu-
mors, and removal of Tregs can effectively enhance the
body’s resistance to tumors [52, 53]. Tregs have a
strong ability to infiltrate and accumulate in tumor tis-
sues. The chemokines in the tumor microenvironment
can bind to the corresponding receptors on the surface
of Tregs, recruit Tregs to the tumor tissues, and exert
immunosuppressive effects [54]. Antigens in tumor tis-
sues can promote the production of Tregs after den-
dritic cell processing and extraction [55]. Tumor cells
secrete cytokines to directly induce the transformation
of T cells into Tregs [56], or indirectly promote the
production of Tregs by inducing the maturation of
myeloid dendritic cells that secrete immunosuppres-
sive factors [57].
Tregs are abundantly present in tumor tissues and
mainly mediate immunosuppressive effects. An in-
creasing number of studies has focused on the meta-
bolic reprogramming of Tregs in tumor tissues and
whether tumors and Tregs can influence each other,
and on how to modulate Tregs or the biologically ac-
tive substances or cells that affect these T cells in the
tumor microenvironment to improve the patient’s
prognosis. Therefore, this review focuses on the meta-
bolic reprogramming of Tregs in tumor tissues and the
effects of the physicochemical properties of the tumor
microenvironment on the generation, proliferation,
and infiltration of Tregs and its mechanisms of action.
Advances in understanding of the complex regulatory
networks of tumor immune evasion provide a theoretical
basis and new biological targets for clinical treatment.
The physiological function of Tregs
Tregs are a subset of T cells that express the interleu-
kin (IL)-2 receptor CD25 and the forkhead/flanking
helix nuclear transcription factor (Foxp3), and were
first discovered in 1995 [58]. Tregs in the body are di-
vided into two groups: natural Tregs (nTregs), which
mature after positive and negative selection of the thy-
mus and exert immunosuppressive effects in peripheral
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blood and lymphoid tissues; and inducible Tregs
(iTregs), which originate after T cells receive antigen
stimulation and are transformed by inhibitory cyto-
kines [59], having differentiated into different subtypes
by different cytokines and playing different biological
roles [60] (Fig. 1/Table. 1).
Foxp3 is a key transcription factor of Tregs, mainly
related to the development and function of these
cells. Foxp3 regulates the immunosuppressive func-
tion of Tregs mainly through transcriptional co-regu-
latory proteins, including transcription factors,
co-repressors, co-activators, histones, and chromatin
remodeling factors, which combine to form protein
complexes to dynamically regulate the expression of
related genes [61–65].
Tregs exert immunosuppressive effects by inhibiting
effector T cells and dendritic cells mainly through the
following pathways: (a) secretion of perforin and gran-
zyme B that act directly on effector cells promoting
apoptosis [66]; (b) secretion of inhibitory cytokines
such as transforming growth factor (TGF)-β, IL-10,
and IL-35 that bind to immune cells and result in im-
munosuppressive effects [67]; (c) by interacting with
target cells via its surface receptors, such as cytotoxic
T lymphocyte-associated antigen (CTLA)-4, to inhibit
immune function by binding to CD80/CD86 on the
surface of effector cells [68], thereby inducing effector
cells to secrete indoleamine 2,3 dioxygenase (IDO),
which catalyzes the conversion of tryptophan in tissues
to kynurenine. The loss of tryptophan inhibits the acti-
vation of effector cells and induces apoptosis [69] .
The increased kynurenine not only inhibits the im-
mune function of effector cells, but also regulates Treg
proliferation and differentiation by acting on the aro-
matic hydrocarbon receptor (AhR) [70]. Specifically,
invasive Tregs in pancreatic cancer can bind to CD80/
CD86 on the surface of dendritic cells via surface
CTLA-4 to inhibit the function of dendritic cells in tis-
sues, which, in turn, affects the function of cytotoxic
CD8+ T cells to suppress immune responses in
Fig. 1 Differentiation of Tregs. nTregs: mature after thymus undergoes selection and exerts an immune function in the periphery. iTregs: peripheral T cells
stimulated by antigen are converted to different Tregs subtypes by different inhibitory cytokines, secreting different cytokines to play
immunosuppressive roles
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pancreatic cancer [71]. Tregs surface also expresses
costimulatory molecules belonging to the CD28
family----induced costimulatory molecules (ICOS)
[72]. ICOS binds to ICOSL, a receptor on the surface
of effector cells, and promotes the secretion of inhibi-
tory cytokines, especially IL-10 [73]; and (d) conver-
sion of intercellular ATP to adenine through the cell
surface receptors CD73 and CD39, with adenine bind-
ing to the adenosine receptor A2AR on the surface of
effector cells and inhibiting its proliferation and im-
mune function [74]. (Fig. 2).
Effects of metabolic reprogramming on Tregs
As the tumor microenvironment undergoes a series of
changes in physical and chemical properties, Tregs
infiltrating tumor tissues are also metabolically repro-
grammed to meet the needs of differentiation, prolif-
eration, and function. Metabolic reprogramming is
primarily involved in glycolysis, fatty acid oxidation
(FAO), and oxidative phosphorylation (OXPHOS).
Glycolysis is a process in which glucose is degraded in
the cytoplasm to produce pyruvic acid and then re-
duced to lactic acid in an oxygen-deficient state. It
can quickly provide the required energy to the cells,
and the metabolites can participate in the growth and
function of the cells as substrates for other reactions.
FAO is a process in which intracellular fatty acids are
oxidatively decomposed into CO2 and H2O by the ac-
tion of related enzymes and release a large amount of
energy. OXPHOS mainly occurs in mitochondria, the
process by which the metabolically produced active
substance is electronically coupled through the respiratory
chain to ultimately couple to form ATP. These metabolic
changes interact to affect the immune function of Tregs.
Reprogramming of glucose metabolism affects Treg
chemotaxis and immune function
In activated Tregs, the surface molecule CD28 is stim-
ulated to activate the downstream PI3K protein, which
stimulates downstream mTORC2 activation and ultim-
ately promotes glucokinase (GCK) expression. On the
one hand, GCK can bind to actin to promote the re-
arrangement of the cytoskeleton and promote the
migration of Tregs into tumor tissues. On the other
hand, as an isozyme of hexokinase, it can promote gly-
colysis in Tregs and provide energy for the movement
of the cytoskeleton [75].
The Toll-like receptor (TLR) on the surface of Tregs
is also involved in metabolic reprogramming. After
stimulation by the microenvironment, TLR1 and TLR2
activate the downstream PI3K-Akt-mTORC1 signaling
pathway, resulting in the expression of glucose trans-
porter 1 on the cell membrane. Glut1 can transport
extracellular glucose into cells for glycolysis, providing
the required energy for Tregs, which is beneficial to
their proliferation, but the activation of this signaling
pathway impairs the immunosuppressive function of
these cells [76]. IL-2 and its receptors are also involved
in the activation of the PI3K-Akt-mTORC1 signaling
pathway [77]. The inhibitory effect on Tregs is a result
of the expression of the transcription factor Foxo1/3
required for inhibition of Foxp3 expression by Akt in
the signaling pathway [78, 79]. However, FOXp3 can
inhibit Tregs glycolysis by inhibiting the PI3K-Akt-
mTORC1 signaling pathway through feedback regula-
tion [76], and, at the same time, inhibits the expression
of the transcription factor Myc [80]. As a growth fac-
tor, Myc can induce cells to undergo metabolic repro-
gramming such as the shift from glycolysis [81], thus
indirectly inhibiting glycolysis in the cell. AMP kinase
(AMPK) inhibits the expression of Glut1 and glycolysis
in Tregs by inhibiting the mTORC1 signaling pathway
[82]. It is speculated that glycolysis may play different
roles in different functional phases of Tregs. (Fig. 3).
Lipid metabolism reprogramming promotes Treg immune
function
AMPK expressed in Tregs is not only involved in the
reprogramming of glucose metabolism, but also pro-
motes FAO by increasing the expression of FAO’s key
enzyme, carnitine palmitoyltransferase-1A (CPT1A)
[83]. PD-1 on the surface of Tregs can also promote
FAO by increasing the expression of CPT1A [84].
Treg’ FAO process promotes Treg proliferation, stabil-
ity, and immunosuppressive function.
Table 1 Treg subtypes and functions
Treg classification Treg subtype Stimulus factor Secretion factor Biological role
Natural Tregs (nTregs) CD4 + CD25 + Foxp3 + nTregs Antigen Perforin, Granzyme B Curbs the occurrence of autoimmune diseases
and induces transplant tolerance
Inducible Tregs (iTregs) CD4 + CD25 + Foxp3 + iTregs TGF-β, IL-2 IL-10, IL-35, TGF-β Maintains the stability of the internal environment,
curbs the occurrence of autoimmune diseases,
anti-tumor immunity, and anti-infective immunity
CD4 + CD25-Foxp3- Tr1 IL-10 IL-10, TGF-β Inflammatory autoimmunity
CD4 + CD25-Foxp3+ Th3 TGF-β TGF-β Participates in oral tolerance and mucosal immunity
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Oxidative phosphorylation promotes Tregs immune
function
Foxp3, the most important transcription factor in
Tregs, promotes mitochondrial OXPHOS by increas-
ing the expression of mitochondria-associated genes
and mitochondrial electron transport system proteins.
These changes not only provide the energy needed for
Tregs to exert immunosuppressive function, but also
consume long-chain fatty acids in cells and protect
from fatty acid-induced apoptosis [85]. Metabolic re-
active oxygen species (ROS) produced during the
OXPHOS process also stabilize the transcription
factor-activated T cell nuclear factor (NFAT) in the nu-
cleus [86], which binds to the non-coding sequence 2
(CNS2) of the enhancer upstream of the Foxp3 gene
[87] and promotes its expression. (Fig. 4).
Treg’ metabolic reprogramming mainly inhibits gly-
colysis and promotes FAO and OXPHOS, so that cells
can adapt to changes in a tumor microenvironment with
low glucose and high lactic acid and promote cell prolif-
eration, differentiation and immune function.
Effects of microenvironmental changes on Tregs
Hypoxia in the microenvironment leads to high ex-
pression levels of the transcriptional regulatory factor,
HIF, in tissue cells, which are positively correlated with
the degree of hypoxia [88]. HIF is a transcriptionally
Fig. 2 Immunosuppression of Tregs. (a)Tregs secrete granzyme B and perforin that act on effector cells and cause apoptosis. (b)Tregs secrete
inhibitory cytokines that bind to receptors on the surface of effector cells and inhibit the immune response. (c) CTLA-4 on the surface of Tregs
competes with CD80/CD86 on the surface of effector cells to inhibit their immune function and promote the secretion of IDO; IDO degrades
tryptophan in tissues to kynurenine; deletion of tryptophan leads to effector cell apoptosis; and kynurenine promotes effector cell apoptosis and
acts on Tres’s AhR to promote its proliferation. ICOS on the surface of Tregs binds to ICOSL on the surface of effector cells, promoting the
effector cell secretion inhibitory cytokine IL-10. (d) CD73/CD39 on the surface of Tregs convert ATP in tissues to adenine, which binds to
receptors on the surface of effector cells and inhibit their immune function
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active heterodimer consisting of an α-subunit and a β-
subunit. HIF-α has three subtypes: HIF-1α, HIF-2α,
and HIF-3α [89]. HIF binds to hypoxia response ele-
ments (HREs) to promote the transcription of related
downstream genes and to express the encoded protein
to respond to the effects of hypoxia on cells [90].
The acidic microenvironment not only promotes the
release of active substances such as immunosuppres-
sive cytokines by affecting the intracellular metabolic
environment, but also affects the biological and phys-
ical properties of tumor cell membranes to promote
exosome release [91]. Exosomes are small vesicles con-
taining complex RNA and proteins for information ex-
change between cells [92].Caveolin-1 can also promote
the release of tumor-derived exosomes under acidic
conditions [91]. Similarly, microenvironment hypoxia
may promote the secretion of exosomes by tumor cells
by activating the HIF signaling pathway [93].
Fig. 3 Effect of glycolysis on Tregs. CD28 on the surface of Tregs is activated to promote GCK expression via PI3K/mTORC2, GCK, and actin, which
can promote cytoskeletal remodeling, and GCK can promote glycolysis to provide energy. Upon stimulation of TLR1/2 or IL-2R on the Treg
surface, activation of the PI3K/AKT/mTORC1 signaling pathway promotes Glut1 expression on the cell membrane surface and promotes glycolysis
to promote proliferation. Akt inhibits the function of Tregs by inhibiting the expression of Foxp3, which in turn inhibits the transcription factor
Foxo1/3. Foxp3 inhibits glycolysis by inhibiting the signaling pathway of PI3K/AKT/mTORC1 and the expression of Myc. AMPK in Tregs inhibits
glycolysis by suppressing mTORC1
Fig. 4 Effect of FAO and OXPHOS on Tregs. AMPK in Tregs promotes FAO by increasing the expression of CPT1A. PD-1 on the surface of Tregs
also promotes FAO by increasing CPT1A expression. Foxp3 promotes OXPHOS by increasing the expression of mitochondria-associated proteins,
ROS, a by-product of OXPHOS, stabilizes NFAT in the nucleus and binds to CNS2 to promote Foxp3 expression
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Microenvironment chemotactic signals recruit Tregs to
tumor tissue
Changes in the tumor microenvironment can affect the
levels of infiltrating cell-associated chemokines in
tumor cells and tissues. These chemokines, in turn, re-
cruit Tregs to tumor tissues by chemotaxis to exert
immunosuppressive effects.
Chemokines are a class of cytokines that are expressed
on the cell surface or secreted into the cell mesenchyme
and have a chemotactic effect on certain cell types. Chemo-
taxis is exerted by binding to the corresponding chemokine
receptors on the cell surface. Chemokine receptors are G
protein-coupled receptors that are widely expressed in vari-
ous cells and are also divided into four families based on
the corresponding ligands. A cross-activation between re-
ceptor and ligand is also observed.
Under hypoxia, ovarian cancer cell lines express a
large number of CCL28 receptors and recruit Tregs to
tumor tissues. HIF-1α inhibitors reduce CCL28 levels
and decrease its chemotactic ability to recruit Tregs. It
is speculated that ovarian cancer cells promote the ex-
pression of CCL28 on the cell surface through the HIF
signaling pathway during hypoxia, and CCL28 interacts
with CCR10 on the surface of Tregs to recruit it by
chemotaxis into the tumor tissue and exert immuno-
suppressive effects [94]. The same findings were ob-
served in liver cancer cell lines [95].
Under hypoxic conditions, basal-like breast cancer
cells exert immunosuppressive effects by affecting the
expression of chemokine receptors on the surface of
Tregs. HIF acts on HREs to promote the expression
of CXCR4 on the surface of Tregs cells, which in turn
bind to CXCL12 on the surface of tumor cells, and
then Tregs are recruited by chemotaxis into tumor
tissues. In addition to its direct action, HIF-1α can
also promote the expression of downstream Foxp3 by
binding to HREs, and indirectly promote the expres-
sion of CXCR4 by acting on regulatory sequences up-
stream of the CXCR4 transcription initiation site [96].
This phenomenon was also observed in ovarian can-
cer [97], lung adenocarcinoma [98], and malignant
mesothelioma [99].
Nasopharyngeal carcinoma cells secrete exosomes
under the influence of the microenvironment to recruit
Tregs by chemotaxis. Tumor-derived exosomes con-
tain CCL20, which is released in the interstitial space
and then binds to CCR6 on the surface of Tregs. These
cells are recruited by chemotaxis to the tumor tissue
and exert immunosuppressive effects [100].
The tumor microenvironment can directly recruit
activated Tregs by chemotaxis into tumor tissues, or
recruit T cells into tumor tissues that differentiate into
Tregs under the stimulation of certain cytokines to
exert immunosuppressive effects (Fig. 5).
Microenvironment promotes differentiation of T cells into
Tregs
A large number of T cells are found infiltrating in the
tumor tissue. These T cells can differentiate into im-
mune cells of several subtypes under the influence of
different cytokines in the microenvironment, thus
exerting different immune effects.
HIF-1α in CD4+ T cells is stably expressed under
hypoxia and binds to HIF-1β in the nucleus. Subse-
quent binding to conserved HIF-1 binding sites on
HREs promotes downstream expression of Foxp3 [101,
102]. As the main transcription factor of Tregs, Foxp3
can regulate most gene expression related to Treg dif-
ferentiation, proliferation, and immune function.
The above process is further improved [103]. The down-
stream regulatory genes of HIF-1 also include TGF-β, and
hypoxia can promote the expression of TGF-β in CD4+ T
cells. On the one hand, TGF-β is secreted into the cell
mesenchyme and binds to the corresponding receptors on
the cell membrane to activate downstream signaling path-
ways and regulate cell differentiation. On the other hand,
TGF-β can inhibit the key enzyme PHD2 [104] in the
proteasome-mediated degradation of HIF-1α, and thus in-
directly promote the expression of HIF-1α in T cells.
Hypoxia not only directly promotes the conversion
of T cells into Tregs, but also indirectly promotes the
differentiation of T cells into Tregs by affecting the se-
cretion of cytokines or enhancing the expression of cell
surface molecules in cells infiltrating tumor tissues.
Immunohistochemistry showed co-localization of HIF-
1α and TGF-β in gastric cancer, suggesting that HIF-1
combined with HREs also promote the expression of
downstream TGF-β molecules in gastric cancer cells.
Subsequently, TGF-β is secreted into the cytoplasm
and binds to the TGF-β receptor on the T cell
membrane, promoting the downstream phosphoryl-
ation of SMAD3. The phosphorylated SMAD3 binds to
SMAD4 and then the complex enters the nucleus,
recruiting the coactivator CBP/p3000 and then binding
to Foxp3 regulatory sequences to promote Foxp3
expression [105].
Programmed cell death protein-1(PD-1) is an active
molecule that is widely expressed on the surface of T
cells and B cells. It can bind to programmed
death-ligand-1(PD-L1) and initiate downstream signal-
ing pathways, regulating the activation of immune
cells. Under hypoxic conditions, HIF-1α in tumor cells,
bone marrow-derived suppressor cells, and dendritic
cells promotes the expression of downstream PD-L1
by acting on HREs. PD-L1 binds to PD-1 on the sur-
face of T cells, causing the dephosphorylation of the
downstream protein PI3K, which in turn inhibits the
activation of downstream AKT/mTOR to promote the
expression of Foxp3 [106]. In renal cell carcinoma,
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hypoxia mainly promotes the expression of PD-L1 by
stabilizing the expression of HIF-2α, and then PD-1
binds to the surface of T cells to promote differenti-
ation into Tregs [107] (Fig. 6).
Tumor-derived exosomes contain TGF-β and IL-10
[108–110] and release their contents after secretion
from cells. TGF-β binds to receptors on the surface of
T cells and differentiates into Tregs by activating the
downstream SMAD signaling pathway. However, bind-
ing of IL-10 to the IL-10R on the surface of T cells
activates downstream JAKs and activates the transcrip-
tion factor STAT3 through phosphorylation of related
molecules. Acting on STAT binding elements pro-
motes the expression of Foxp3, which differentiates T
cells into Tregs. Tumor-derived exogenous TGF-β may
have a greater impact on Tregs because IL-10 can only
induce T-cell differentiation into Tregs, whereas
TGF-β can promote Tregs proliferation in addition to
inducing differentiation.
In addition to immunosuppressive cytokines, tumor-de-
rived exosomes also contain microRNAs (miRs) that regu-
late cell differentiation. Exosomes containing miR-214 can
directly bind to the T cell membrane, transferring
miR-214 into T cells by endocytosis, which not only pro-
motes the secretion of IL-10 by T cells, but also binds to
the 3’UTR region of PTEN, reduces the expression of
PTEN protein in cells, and activates the PI3K-Akt signal-
ing pathway [111]. This signaling pathway enables the
intracellular accumulation of the cycle-associated tran-
scription factor E2F to promote the proliferation of Tregs
[112]. PTEN is also a major regulator of Treg stability. A
large number of PTEN deletions in Tregs affect PI3K-Akt
regulation, leading to CD25 deletion, and the accumula-
tion of Foxp3 + CD25-T cells ultimately leads to the loss
of Foxp3 expression in these cell populations; therefore,
PTEN regulates Treg lineage homeostasis and stability by
inhibiting the PI3K-Akt signaling pathway [113]. More-
over PTEN can also promote the induction of the
JAK-STAT signaling pathway to promote the expression of
FOXp3 [114] (Fig. 7).
The metabolite, RA, promotes differentiation of T cells
into Tregs
Metabolites in the microenvironment can also affect
the function of Tregs. Retinoic acid (RA) is a metabol-
ite of vitamin A in dendritic cells [115]. The ability of
RA to directly induce the differentiation of T cells into
Tregs is weak; however, it can significantly enhance
the efficiency of TGF-β and IL-2 to promote the differ-
entiation of T cells into Tregs [116]. As an important
molecule that promotes the function of Tregs, IL-2
can promote the expression of Foxp3 by activating the
Fig. 5 The microenvironment recruits Tregs to tumor tissue by chemotaxis. Hypoxia promotes the expression of chemokines on tumor cells and
Tregs surface through the HIF signaling pathway, and recruits Tregs by chemotaxis to the tumor tissue. Low pH microenvironment promotes the
secretion of chemokine-containing exosomes from tumor cells that recruit Tregs to tumor tissue by chemotaxis
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downstream JAK/STAT5 signaling pathway by binding
to the IL-2 receptor [117]. RA indirectly affects the
quantity and function of infiltrating Tregs in tumor
tissues. (Fig. 8).
Conclusions
Owing to their rapid proliferation and invasion and
metastasis characteristics, tumor cells have large differ-
ences in their metabolic activities from normal cells.
There are many cell types that infiltrate the micro-
environment in which the tumor cells are located, in-
cluding immune cells and mesenchymal cells [118].
Changes in metabolic activity and an increase in infil-
trating cells lead to a change in the physicochemical
properties of the tumor microenvironment, the most
notable of which are hypoxia and pH reduction. Meta-
bolic reprogramming and microenvironmental changes
will cause changes in cell-associated transcription fac-
tors and secretory substances, which will affect the oc-
currence and development of tumors.
Tregs are T cells that suppress immunity and heavily
infiltrate tumor tissues, regulating tumor proliferation,
invasion, and metastasis. Metabolic reprogramming
and microenvironmental changes generally play a role
in promoting the function of Tregs: i) invasion of
Tregs into tumor tissue by cytoskeletal rearrangement
or secretion of chemokines; ii) induce of transcription
factors or suppressive cytokines that promote the dif-
ferentiation of T cells into Tregs; and iii) stimulation of
the immunosuppressive function by regulating metab-
olism or promoting Treg secretion of functional cyto-
kines. There are probably still chemokines, cytokines,
and relevant signaling pathways to be discovered with
the above modes of action. The effects of metabolism
on Tregs are two-sided. Glycolysis can promote the
proliferation of Tregs but it inhibits its immunosup-
pressive function. The metabolites of glycolysis can
participate in other metabolic activities that promote
Treg function. The effects of metabolic reprogram-
ming on Tregs are not limited to the role of a single
signaling pathway or a single type of metabolism.
Instead, they are affected by changes in the micro-
environment to regulate the cell function. The key
transcription factor, HIF-1α, in the tumor microenvir-
onment is also bidirectional in regulating Tregs. The
expression of HIF-1α is increased under hypoxia. On
one hand, it can inhibit the differentiation of Tregs by
Fig. 6 Hypoxia induces differentiation of T-cells to Tregs. T cells directly promote the expression of Foxp3 through the HIF signaling pathway. T
cells promote the expression of TGF-β through HIF signaling, inhibit the key enzyme PHD2 for HIF-1α degradation, and indirectly promote the
expression of Foxp3. Tumor cells promote the expression of TGF-β through the HIF signaling pathway, act on the receptors on the surface of T
cells, activate the downstream SMAD signaling pathway, and promote the expression of Foxp3.Tumor cells promote the expression of PD-L1 on
the cell surface through the HIF signaling pathway, bind PD-1 on the surface of T cells, inhibit the downstream AKT and mTOR pathways, and
promote the expression of Foxp3
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Fig. 8 Effects of the metabolite, RA, on Tregs. RA in the microenvironment promotes the expression of Foxp3 by promoting the activation of the
downstream JAK/STAT5 signaling pathway by IL-2 and the activation of the downstream SMAD signaling pathway by TGF-β, indirectly promoting
the differentiation and proliferation of Tregs
Fig. 7 Low pH induces differentiation of T cell into Tregs. Tumor-derived exosomes contain TGF-β, which acts on the receptor on the surface of
T cells to activate the SMAD signaling pathway and promote the expression of Foxp3. Tumor-derived exosomes contain IL-10, which acts on
receptors on the T cell surface to activate the JAK/STAT signaling pathways and promote Foxp3 expression. Tumor-derived exosomes contain
miR-214, which enters Tregs by endocytosis, inhibits the expression of PTEN protein, and then promotes the expression of the cycle-related
transcription factor E2F by activating the PI3K signaling pathway and promote Tregs proliferation. PTEN maintains the stability of Tregs by
inhibiting the activation of PI3K/Akt to stabilize the expression of CD25 and promotes the induction of the JAK-STAT signaling pathway to
maintains the stability of Tregs
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promoting glycolysis [119, 120], and on the other
hand, it can promote the expression of Foxp3 and
promote the differentiation of Tregs. The above
phenomenon may be due to the different means of
regulating the expression level of HIF-1α in cells. Dif-
ferent cytokines stimulates HIF-1α to activate different
downstream signaling pathways, which leads to differ-
ent functions of regulatory T cells [120]. Intracellular
feedback regulation also affects the function of HIF-1α.
Tregs affects its function according to the stimulation
and regulation inside and outside the cell. In addition
to traditional methods of regulation, non-coding RNAs
can also affect the function of Tregs. miRs can be se-
creted by cells in exosomes, and then modulate the
Tregs to act on the corresponding target regulatory
cells. There are many kinds of non-coding RNAs, and
their mode of action is complex. Further research is
necessary to explore these regulatory mechanisms of
Treg function. Many of the above experiments were
performed in vitro, failing to completely simulate the
complex dynamic balance of the tumor microenviron-
ment, and Tregs are susceptible to this microenviron-
ment. The experimental results may be inconsistent
with the in vivo experiments; therefore, it is necessary
to continue the exploration with rigorous experiments.
In addition to surgical treatment, chemotherapy, and
radiotherapy, immunotherapy has gained increasing at-
tention, including treatment of PD-L1 and its related
signaling pathways [121], inhibitors of CTLA-4 [122],
and CAR-T treatment [123]. Tregs as major immuno-
suppressive cells have an important influence on the
occurrence and development of tumors. Although
large numbers of Tregs are usually associated with
poor clinical outcomes, the role of Tregs in colorectal
cancer [124], head and neck squamous cell carcinoma
[125], and esophageal cancer [49] remains controver-
sial. This may be a result of the presence of chronic in-
flammation in tumor tissue that promotes abnormal
cell proliferation, angiogenesis, and distant metastasis
[126], whereas Tregs act as immunosuppressive cells
that inhibit tumor development by reducing chronic
inflammation. In addition, Tregs can also be divided
into different subtypes according to the expression
levels of Foxp3 and CD45RA, and the prognosis of pa-
tients with colorectal cancer is closely related to the
infiltrating Treg subtype [127]. The complex role of
Tregs in tumor progression may also be affected by the
tumor microenvironment. Changes in tumor micro-
environment and metabolic reprogramming can affect
not only the differentiation of primary T cells into
Tregs, but also its immune suppression function, and
therefore also the balance of Tregs and Th17 by affect-
ing the expression of Foxp3 and RORgt [128, 129]. The
above factors comprehensively affect tumor
progression. Therapeutic methods targeting Tregs are
also receiving increasing attention. However, directly
killing the Tregs in the tumor tissue does not improve
the patient’s condition, because the adenosine pro-
duced by apoptotic Tregs will continue to inhibit the
function of the effector cells [130]. Therefore, inhibit-
ing the migration of Tregs to tumor tissues may have
an effect on the treatment of cancer. Clinical trials
have been conducted for treatment with chemokines,
such as the use of monoclonal antibodies against
CCR4 in the treatment of lymphoma, and a significant
anti-tumor effect has been observed [131]. Regarding
tumor infiltrating Tregs, Tregs can be depleted in
tumor tissues by targeting the Treg surface-specific re-
ceptor, CD25, to inhibit tumor growth. Improving
anti-CD25 antibodies and using them together with
PD-1 antibodies may lead to a better therapeutic effect
[132]. The fusion protein formed by IL-2 and diph-
theria toxin can recognize IL-2R on the surface of
Tregs to clear the cells. Treatment of renal cancer can
effectively reduce the number of Tregs in the body,
thereby achieving the purpose tumors treatments
[133]. In addition to the expression of the transcription
factor Foxp3, Tregs also expresses the transcription
factor, Helios, to maintain stability. Deleting Helios
will lead to the conversion of Tregs into effector T
cells, which significantly delays tumor growth. There-
fore, Helios targeting can be used as a feasible treat-
ment strategy [134]. Similarly, targeting of Foxp3 can
also help to regulate the expression of Tregs [135].
Moreover the treatment based on metabolic repro-
gramming has also been used in some immune dis-
eases [136].
Based on the current status of immunotherapy, re-
search still needs to be performed to improve our un-
derstanding of the mechanism of interaction between
the tumor, Tregs and its subtypes, and other immune
cells. Finding key cytokines, signaling pathways, non-
coding RNAs that are relevant to Treg’ function is
needed, and these will serve as potential targets for im-
munotherapy. The present review, which highlights the
changes in the tumor microenvironment that result in
changes in metabolites and thus affect the function of
Tregs, enriches the theoretical basis of tumor im-
munosuppression, and may provide new directions for
cancer immunotherapy.
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